{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:47:24Z","timestamp":1791031644479,"version":"4.1.0"},"reference-count":127,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The management of multiple myeloma has undergone profound changes over the recent past as a result of advances in our understanding of the disease biology as well as improvements in treatment and supportive care strategies. Notably, recent years have seen a surge in studies incorporating the novel agents thalidomide, bortezomib, and lenalidomide into treatment for different disease stages and across different patient groups. This article presents an update to a previous review of European treatment practices and is based on discussions during an expert meeting that was convened to review novel agent data published or presented at medical meetings until the end of 2011 and to assess their impact on treatment strategies.<\/jats:p>","DOI":"10.1634\/theoncologist.2011-0391","type":"journal-article","created":{"date-parts":[[2012,5,10]],"date-time":"2012-05-10T00:19:22Z","timestamp":1336609162000},"page":"592-606","source":"Crossref","is-referenced-by-count":45,"title":["European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses"],"prefix":"10.1093","volume":"17","author":[{"given":"Heinz","family":"Ludwig","sequence":"first","affiliation":[{"name":"a Wilhelminenspital, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Avet-Loiseau","sequence":"additional","affiliation":[{"name":"b Laboratoire d'H\u00e9matologie, Institut de Biologie, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[{"name":"c Department of Hematology, IDIBAPS, Hospital Clinic, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[{"name":"d Divisione di Ematologia dell'Universit\u00e0 di Torino, Azienda Ospedaliera S. Giovanni Battista, Ospedale Molinette, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Cavenagh","sequence":"additional","affiliation":[{"name":"e Department of Haematology, St Bartholomew's Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"f Institute of Hematology and Medical Oncology, Seragnoli, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith","family":"Davies","sequence":"additional","affiliation":[{"name":"g Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Rubia","sequence":"additional","affiliation":[{"name":"h Hematology Service, University Hospital La Fe, Valencia, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sosana","family":"Delimpasi","sequence":"additional","affiliation":[{"name":"i Evangelismos Hospital Hematology and Bone Marrow Transplantation, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"j Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Drach","sequence":"additional","affiliation":[{"name":"k Department of Oncology, University Clinic, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"l Universit\u00e4tsklinik W\u00fcrzburg, Medizinische Klinik und Poliklinik II, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[{"name":"m Service d'H\u00e9matologie, Centre Hospitalier Universitaire (CHU), Lille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"n Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urs","family":"Hess","sequence":"additional","affiliation":[{"name":"o Division of Oncology\/Hematology, Kantonsspital, St. Gallen, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf-Henrik","family":"Mellqvist","sequence":"additional","affiliation":[{"name":"p Department of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"q University Hospital, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"San-Miguel","sequence":"additional","affiliation":[{"name":"r Servicio de Hematolog\u00eda, Hospital Universitario de Salamanca, CIC, IBMCC (USAL-CSIC), Salamanca, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Sondergeld","sequence":"additional","affiliation":[{"name":"s Ammonite Systems Ltd., Faringdon, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"t Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miklos","family":"Udvardy","sequence":"additional","affiliation":[{"name":"u Institute of Medicine, Medical and Health Science Centre, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[{"name":"d Divisione di Ematologia dell'Universit\u00e0 di Torino, Azienda Ospedaliera S. Giovanni Battista, Ospedale Molinette, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,5,9]]},"reference":[{"key":"2021122308115896100_B1","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99\u201306): A randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"2021122308115896100_B2","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"2021122308115896100_B3","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308115896100_B4","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122308115896100_B5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1182\/blood.V118.21.476.476","article-title":"Continued overall survival benefit after 5 years' follow-up with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with previously untreated multiple myeloma, and no increased risk of second primary malignancies: Final results of the phase 3 VISTA trial [abstract 476]","volume":"118","author":"San Miguel","year":"2011","journal-title":"Blood"},{"key":"2021122308115896100_B6","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122308115896100_B7","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: A randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308115896100_B8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood.V116.21.622.622","article-title":"A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients \u2265 65 years with newly diagnosed multiple myeloma (NDMM): Continuous use of lenalidomide vs fixed-duration regimens [abstract 622]","volume":"116","author":"Palumbo","year":"2010","journal-title":"Blood"},{"key":"2021122308115896100_B9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood.V118.21.475.475","article-title":"A phase 3 study evaluating the efficacy and safety of lenalidomide (Len) combined with melphalan and prednisone followed by continuous lenalidomide maintenance (MPR-R) in patients (pts) \u2265 65 years (yrs) with newly diagnosed multiple myeloma (NDMM): Updated results for pts aged 65\u201375 yrs enrolled in MM-015 [abstract 475]","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"key":"2021122308115896100_B10","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: The HOVON 49 study","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308115896100_B11","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood-2011-03-341669","article-title":"Thalidomide for previously untreated elderly patients with multiple myeloma: Meta-analysis of 1685 individual patient data from 6 randomized clinical trials","volume":"118","author":"Fayers","year":"2011","journal-title":"Blood"},{"key":"2021122308115896100_B12","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1634\/theoncologist.2011-0229","article-title":"Improvement in survival of older adults with multiple myeloma: Results of an updated period analysis of SEER data","volume":"16","author":"Pulte","year":"2011","journal-title":"The Oncologist"},{"key":"2021122308115896100_B13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1634\/theoncologist.2009-0203","article-title":"Current multiple myeloma treatment strategies with novel agents: A European perspective","volume":"15","author":"Ludwig","year":"2010","journal-title":"The Oncologist"},{"key":"2021122308115896100_B14","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1634\/theoncologist.2010-0386","article-title":"Multiple myeloma treatment strategies with novel agents in 2011: A European perspective","volume":"16","author":"Ludwig","year":"2011","journal-title":"The Oncologist"},{"key":"2021122308115896100_B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0609.2010.01542.x","article-title":"Emerging therapies for the treatment of relapsed or refractory multiple myeloma","volume":"86","author":"Dimopoulos","year":"2011","journal-title":"Eur J Haematol"},{"key":"2021122308115896100_B16","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1158\/1078-0432.CCR-10-1805","article-title":"Treatment options for relapsed and refractory multiple myeloma","volume":"17","author":"Lonial","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2021122308115896100_B17","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.2010.34.0760","article-title":"Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma","volume":"29","author":"Mitsiades","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308115896100_B18","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1517\/13543784.2011.575060","article-title":"How to treat patients with relapsed\/refractory multiple myeloma: Evidence-based information and opinions","volume":"20","author":"Offidani","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"2021122308115896100_B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08790.x","article-title":"Monoclonal antibodies in the treatment of multiple myeloma","author":"Richardson","year":"2011","journal-title":"Br J Haematol"},{"key":"2021122308115896100_B20","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","article-title":"International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation","volume":"117","author":"Cavo","year":"2011","journal-title":"Blood"},{"key":"2021122308115896100_B21","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2010.32.5878","article-title":"Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies","volume":"29","author":"Moreau","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308115896100_B22","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005\u201301 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308115896100_B23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122308115896100_B24","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction treatment before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"suppl 1","key":"2021122308115896100_B25","first-page":"S69","article-title":"Results of pre- and post-autologous stem cell transplantation (ASCT) with three induction regimens in multiple myeloma (MM): Superiority of VTD (bortezomib\/thalidomide\/dexamethasone) over TD and VBMCP\/VBAD plus bortezomib (VBMCP\/VBAD\/V) [abstract P-138]","volume":"96","author":"Rosinol","year":"2011","journal-title":"Haematologica"},{"key":"2021122308115896100_B26","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"key":"2021122308115896100_B27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood.V116.21.40.40","article-title":"HOVON-65\/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed Multiple Myeloma (MM) [abstract 40]","volume":"116","author":"Sonneveld","year":"2010","journal-title":"Blood"},{"key":"2021122308115896100_B28","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3324\/haematol.2011.043372","article-title":"Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results","volume":"97","author":"Morgan","year":"2012","journal-title":"Haematologica"},{"key":"2021122308115896100_B29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V114.22.131.131","article-title":"Velcade, intravenous cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM XIa Trial) [abstract 131]","volume":"114","author":"Einsele","year":"2009","journal-title":"Blood"},{"key":"2021122308115896100_B30","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"2021122308115896100_B31","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1182\/blood.V118.21.1872.1872","article-title":"Bortezomib, lenalidomide, and dexamethasone (VRD) consolidation and lenalidomide maintenance in frontline multiple myeloma patients: Updated results of the IFM 2008 phase II VRD intensive program [abstract 1872]","volume":"118","author":"Roussel","year":"2011","journal-title":"Blood"},{"key":"2021122308115896100_B32","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood.V118.21.3069.3069","article-title":"Melphalan\/prednisone\/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) in newly diagnosed multiple myeloma (MM) patients &lt;65 years: Results of a randomized phase III study [abstract 3069]","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"key":"2021122308115896100_B33","volume-title":"THALOMID","author":"U.S. Food and Drug Administration"},{"key":"2021122308115896100_B34","volume-title":"VELCADE","author":"U.S. Food and Drug Administration"},{"key":"2021122308115896100_B35","first-page":"S31","article-title":"Improved progression free survival with bortezomib consolidation after high dose melphalan; results of a randomized phase III trial [abstract O-11]","volume":"96","author":"Mellqvist","year":"2011","journal-title":"Haematologica"},{"key":"2021122308115896100_B36","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood.V118.21.827.827","article-title":"Long-term results of the GIMEMA VTD consolidation trial in autografted multiple myeloma patients (VEL-03\u2013096): Impact of minimal residual disease detection by real time quantitative PCR on late recurrences and overall survival [abstract 827]","volume":"118","author":"Ladetto","year":"2011","journal-title":"Blood"},{"key":"2021122308115896100_B37","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1182\/blood.V118.21.1871.1871","article-title":"Superior complete response rate (CR) and progression-free survival (PFS) with bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as consolidation therapy after autologous stem-cell transplantation (ASCT) in multiple myeloma (MM) [abstract 1871]","volume":"118","author":"Cavo","year":"2011","journal-title":"Blood"},{"key":"2021122308115896100_B38","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood.V116.21.3041.3041","article-title":"Consolidation with bortezomib, thalidomide and dexamethasone after high dose therapy is feasible , safe and effective in de novo multiple myeloma patients who already received new drugs containing-induction regimen [abstract 3041]","volume":"116","author":"Roussel","year":"2010","journal-title":"Blood"},{"key":"2021122308115896100_B39","first-page":"S23","article-title":"Maintenance treatment with lenalidomide after transplantation for myeloma: Analysis of secondary malignancies within the IFM 2005\u201302 trial","volume":"96","author":"Attal","year":"2011","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2021122308115896100_B40","first-page":"S96","article-title":"Molecular remission after bortezomib-thalidomide-dexamethasone (VTD) compared with thalidomide-dexamethasone (TD) as consolidation therapy following double autologous transplantation (ASCT) for multiple myeloma (MM): Results of a qualitative and quantitative analysis [abstract P-224]","volume":"96","author":"Terragna","year":"2011","journal-title":"Haematologica"},{"key":"2021122308115896100_B41","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308115896100_B42","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"2021122308115896100_B43","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2009.25.6081","article-title":"Long-term follow-up of autotransplantation trials for multiple myeloma: Update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences","volume":"28","author":"Barlogie","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308115896100_B44","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122308115896100_B45","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2008-03-145235","article-title":"Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"key":"2021122308115896100_B46","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with Adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"key":"2021122308115896100_B47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"key":"2021122308115896100_B48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood.V116.21.39.39","article-title":"A randomized phase iii trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): The NCIC CTG MY.10 trial [abstract 39]","volume":"116","author":"Stewart","year":"2010","journal-title":"Blood"},{"key":"2021122308115896100_B49","first-page":"S23","article-title":"Phase III Intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB ECOG BMT-CTN 100104","volume":"96","author":"McCarthy","year":"2011","journal-title":"Haematologica"},{"key":"2021122308115896100_B50","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1182\/blood.V118.21.3962.3962","article-title":"A phase III PETHEMA\/GEM randomized trial of postransplant (ASCT) maintenance in multiple myeloma: Superiority of bortezomib\/thalidomide compared with thalidomide and alfa-2b interferon [abstract 3962]","volume":"118","author":"Rosi\u00f1ol","year":"2011","journal-title":"Blood"},{"key":"2021122308115896100_B51","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1200\/JCO.2009.24.0150","article-title":"Thalidomide maintenance in multiple myeloma: Certainties and controversies","volume":"27","author":"Cavo","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308115896100_B52","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","article-title":"Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p","volume":"119","author":"Neben","year":"2012","journal-title":"Blood"},{"key":"2021122308115896100_B53","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2011-11-374249","article-title":"IMWG consensus on maintenance therapy in multiple myeloma","volume":"119","author":"Ludwig","year":"2012","journal-title":"Blood"},{"key":"2021122308115896100_B54","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2011-02-338665","article-title":"Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation","volume":"118","author":"Morgan","year":"2011","journal-title":"Blood"},{"key":"2021122308115896100_B55","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00432-005-0074-4","article-title":"Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone\u2014a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)","volume":"132","author":"P\u00f6nisch","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"2021122308115896100_B56","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood.V116.21.308.308","article-title":"Lenalidomide plus low-dose dexamethasone (Ld): Superior one and two year survival regardless of age compared to lenalidomide plus high-dose dexamethasone (LD) [abstract 308]","volume":"116","author":"Vesole","year":"2010","journal-title":"Blood"},{"key":"2021122308115896100_B57","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized, controlled trial","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"2021122308115896100_B58","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1182\/blood.V118.21.477.477","article-title":"Maintenance therapy with bortezomib plus thalidomide (VT) or bortezomib plus prednisone (VP) in elderly myeloma patients included in the GEM2005MAS65 Spanish randomized trial [abstract 477]","volume":"118","author":"Mateos","year":"2011","journal-title":"Blood"},{"key":"2021122308115896100_B59","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1200\/JCO.2009.25.2114","article-title":"Survival and years of life lost in different age cohorts of patients with multiple myeloma","volume":"28","author":"Ludwig","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308115896100_B60","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"key":"2021122308115896100_B61","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122308115896100_B62","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"2021122308115896100_B63","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021122308115896100_B64","volume-title":"Label approved on 01\/23\/2012 for VELCADE, NDA no. 021602","author":"U.S. Food and Drug Administration"},{"key":"2021122308115896100_B65","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1200\/JCO.2010.29.7929","article-title":"International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma","volume":"28","author":"Lokhorst","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308115896100_B66","article-title":"Thalidomide versus dexamethasone for the treatment of relapsed and\/or refractory multiple myeloma: results from OPTIMUM, a randomized trial","author":"Kropff","year":"2011","journal-title":"Haematologica"},{"key":"2021122308115896100_B67","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"2021122308115896100_B68","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"2021122308115896100_B69","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2021122308115896100_B70","first-page":"S72","article-title":"Bortezomib (VELCADE)-thalidomide-dexamethasone (VTD) is superior to thalidomide-dexamethasone (TD) in patients with multiple myeloma (MM) progressing or relapsing after autologous transplantation [abstract P-150]","volume":"96","author":"Garderet","year":"2011","journal-title":"Haematologica"},{"key":"2021122308115896100_B71","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.seminhematol.2009.01.004","article-title":"Treatment of relapsed\/refractory multiple myeloma","volume":"46","author":"Kastritis","year":"2009","journal-title":"Semin Hematol"},{"key":"2021122308115896100_B72","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1038\/leu.2009.179","article-title":"The use of novel agents in the treatment of relapsed and refractory multiple myeloma","volume":"23","author":"Laubach","year":"2009","journal-title":"Leukemia"},{"issue":"suppl 2","key":"2021122308115896100_B73","first-page":"22","article-title":"Tailoring treatment for multiple myeloma patients with relapsed and refractory disease","volume":"24","author":"Richardson","year":"2010","journal-title":"Oncology (Williston Park)"},{"key":"2021122308115896100_B74","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/asheducation-2010.1.303","article-title":"Relapsed multiple myeloma","volume":"2010","author":"Lonial","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021122308115896100_B75","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-3-540-85772-3_11","article-title":"Therapy of relapsed and refractory multiple myeloma","volume":"183","author":"Moehler","year":"2011","journal-title":"Recent Results Cancer Res"},{"key":"2021122308115896100_B76","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ctrv.2010.08.008","article-title":"Treatment of relapsed and refractory multiple myeloma in the era of novel agents","volume":"37","author":"Donk","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"2021122308115896100_B77","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/asheducation.V2010.1.310.3645859","article-title":"Evidence-based mini-review: Treatment options for patients with relapsed\/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation","volume":"2010","author":"Shah","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021122308115896100_B78","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2008-02-141614","article-title":"Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure","volume":"112","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"2021122308115896100_B79","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1182\/blood-2011-04-350009","article-title":"Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma","volume":"118","author":"Madan","year":"2011","journal-title":"Blood"},{"key":"2021122308115896100_B80","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ajh.21517","article-title":"Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib","volume":"84","author":"Sood","year":"2009","journal-title":"Am J Hematol"},{"key":"2021122308115896100_B81","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000322866","article-title":"Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland","volume":"79","author":"Hrusovsky","year":"2010","journal-title":"Oncology"},{"issue":"suppl 2","key":"2021122308115896100_B82","first-page":"152","article-title":"Efficacy and safety of retreatment with bortezomib in patients with multiple myeloma: Interim results from RETRIEVE, a prospective international phase 2 study [abstract 377]","volume":"95","author":"Petrucci","year":"2010","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2021122308115896100_B83","first-page":"S86","article-title":"Bortezomib retreatment in patients with relapsed multiple myeloma in Switzerland [abstract P-193]","volume":"96","author":"Taverna","year":"2011","journal-title":"Haematologica"},{"key":"2021122308115896100_B84","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: A consensus statement on behalf of the International Myeloma Working Group","volume":"28","author":"Dimopoulos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2021122308115896100_B85","first-page":"127","article-title":"Lenalidomide-dexamethasone (LD) as treatment of acute cast nephropathy-induced renal failure (ARF) in multiple myeloma (MM). A phase II study [abstract 306]","volume":"96","author":"Ludwig","year":"2011","journal-title":"Haematologica"},{"key":"2021122308115896100_B86","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"2021122308115896100_B87","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","article-title":"Treatment-related peripheral neuropathy in multiple myeloma: The challenge continues","volume":"11","author":"Delforge","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122308115896100_B88","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3324\/haematol.2009.012674","article-title":"Peripheral neuropathy and new treatments for multiple myeloma: Background and practical recommendations","volume":"95","author":"Mohty","year":"2010","journal-title":"Haematologica"},{"key":"2021122308115896100_B89","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1182\/asheducation-2010.1.423","article-title":"Dealing with neuropathy in plasma-cell dyscrasias","volume":"2010","author":"Sonneveld","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021122308115896100_B90","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma","volume":"26","author":"Richardson","year":"2012","journal-title":"Leukemia"},{"key":"2021122308115896100_B91","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3816\/CLML.2010.n.120","article-title":"Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone","volume":"11","author":"San-Miguel","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2021122308115896100_B92","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/cncr.25743","article-title":"The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens","volume":"117","author":"Benevolo","year":"2011","journal-title":"Cancer"},{"key":"2021122308115896100_B93","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00277-011-1217-0","article-title":"Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation\/maintenance therapy in patients with relapsed-refractory multiple myeloma","volume":"90","author":"Offidani","year":"2011","journal-title":"Ann Hematol"},{"key":"2021122308115896100_B94","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood-2010-10-300970","article-title":"Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2","volume":"117","author":"Munshi","year":"2011","journal-title":"Blood"},{"key":"2021122308115896100_B95","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.clml.2011.07.001","article-title":"Increased serum lactate dehydrogenase should be included among the variables that define very-high-risk multiple myeloma","volume":"11","author":"Gkotzamanidou","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2021122308115896100_B96","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","article-title":"Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"2021122308115896100_B97","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-010-9521-4","article-title":"Treatment options for multiple myeloma patients with high-risk disease","author":"Ailawadhi","year":"2010","journal-title":"Med Oncol"},{"key":"2021122308115896100_B98","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ajh.21913","article-title":"Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"Rajkumar","year":"2011","journal-title":"Am J Hematol"},{"key":"2021122308115896100_B99","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1182\/blood-2011-06-297853","article-title":"Approach to the treatment of multiple myeloma: A clash of philosophies","volume":"118","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"2021122308115896100_B100","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2141.2011.08791.x","article-title":"Managing multiple myeloma: The emerging role of novel therapies and adapting combination treatment for higher risk settings","volume":"154","author":"Richardson","year":"2011","journal-title":"Br J Haematol"},{"key":"2021122308115896100_B101","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2009-11-255620","article-title":"Superior results of Total Therapy 3 (2003\u201333) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006\u201366 with VRD maintenance","volume":"115","author":"Nair","year":"2010","journal-title":"Blood"},{"key":"2021122308115896100_B102","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","article-title":"Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)","volume":"28","author":"Avet-Loiseau","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308115896100_B103","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1200\/JCO.2010.32.8435","article-title":"Molecular heterogeneity of multiple myeloma: Pathogenesis, prognosis, and therapeutic implications","volume":"29","author":"Avet-Loiseau","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308115896100_B104","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1182\/blood.V116.21.781.781","article-title":"Bortezomib-based induction treatments improve outcomes of newly diagnosed multiple myeloma patients with high-risk cytogenetic abnormalities [abstract 781]","volume":"116","author":"Cavo","year":"2010","journal-title":"Blood"},{"key":"2021122308115896100_B105","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrclinonc.2011.63","article-title":"Treatment of multiple myeloma","volume":"8","author":"Rajkumar","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"suppl 6","key":"2021122308115896100_B106","first-page":"199","article-title":"Up front allogeneic stem cell transplant is superior to tandem high-dose melphalan in cytogenetically defined ultra high-risk myeloma [abstract V677]","volume":"34","author":"Knop","year":"2011","journal-title":"Onkologie"},{"key":"2021122308115896100_B107","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"2021122308115896100_B108","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1038\/leu.2011.147","article-title":"MicroRNA signatures characterize multiple myeloma patients","volume":"25","author":"Corthals","year":"2011","journal-title":"Leukemia"},{"key":"2021122308115896100_B109","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3324\/haematol.2010.037978","article-title":"Cancer testis antigens in newly diagnosed and relapse multiple myeloma: Prognostic markers and potential targets for immunotherapy","volume":"96","author":"Duin","year":"2011","journal-title":"Haematologica"},{"key":"2021122308115896100_B110","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"2021122308115896100_B111","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1200\/JCO.2007.13.8545","article-title":"Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: A study of the Intergroupe Francophone du My\u00e9lome","volume":"26","author":"Decaux","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308115896100_B112","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","article-title":"Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients","volume":"116","author":"Broyl","year":"2010","journal-title":"Blood"},{"key":"2021122308115896100_B113","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-09-2831","article-title":"Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome","volume":"16","author":"Dickens","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021122308115896100_B114","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1182\/blood-2011-03-342089","article-title":"Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone","volume":"118","author":"Kumar","year":"2011","journal-title":"Blood"},{"key":"2021122308115896100_B115","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3324\/haematol.2010.033456","article-title":"A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines","volume":"96","author":"Moreaux","year":"2011","journal-title":"Haematologica"},{"key":"2021122308115896100_B116","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","article-title":"A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value","volume":"116","author":"Walker","year":"2010","journal-title":"Blood"},{"key":"2021122308115896100_B117","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cancergencyto.2010.11.002","article-title":"The prognostic significance of cytogenetics and molecular profiling in multiple myeloma","volume":"204","author":"Sawyer","year":"2011","journal-title":"Cancer Genet"},{"key":"2021122308115896100_B118","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1182\/blood-2008-02-140434","article-title":"Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping","volume":"112","author":"Johnson","year":"2008","journal-title":"Blood"},{"key":"2021122308115896100_B119","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1470-2045(10)70206-0","article-title":"Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: A prospective analysis of data from the HOVON-65\/GMMG-HD4 trial","volume":"11","author":"Broyl","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122308115896100_B120","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.3324\/haematol.2011.041434","article-title":"Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients","volume":"96","author":"Corthals","year":"2011","journal-title":"Haematologica"},{"key":"2021122308115896100_B121","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/FPC.0b013e3283436b45","article-title":"Genetic variation associated with bortezomib-induced peripheral neuropathy","volume":"21","author":"Favis","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"2021122308115896100_B122","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.2010.28.0792","article-title":"Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma","volume":"29","author":"Johnson","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308115896100_B123","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/pmic.201000471","article-title":"A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients","volume":"11","author":"Rajpal","year":"2011","journal-title":"Proteomics"},{"key":"2021122308115896100_B124","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter International Myeloma Working Group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"2021122308115896100_B125","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/sj.bmt.1704757","article-title":"Cure of myeloma: Hype or reality?","volume":"35","author":"Fassas","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"2021122308115896100_B126","first-page":"S10","article-title":"Genomics and cure in multiple myeloma [abstract]","volume":"96","author":"Barlogie","year":"2011","journal-title":"Haematologica"},{"key":"2021122308115896100_B127","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.3324\/haematol.2011.051169","article-title":"Can multiple myeloma become a curable disease?","volume":"96","author":"San-Miguel","year":"2011","journal-title":"Haematologica"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2011-0391","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0391","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/5\/592\/41860784\/oncolo_17_5_592.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/5\/592\/41860784\/oncolo_17_5_592.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T19:32:57Z","timestamp":1640287977000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/5\/592\/6403377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,1]]},"references-count":127,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2012,5,9]]},"published-print":{"date-parts":[[2012,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0391","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,5,1]]},"published":{"date-parts":[[2012,5,1]]}}}